https://pepsreview.com/articles/celltrion-four-target-obesity-drug-mouse-study PepsReview en 2026-11-04 Celltrion CT-G32, quadruple agonist, obesity drug pipeline, GLP-1, retatrutide, preclinical data, IND filing, lean mass preservation https://pepsreview.com/articles/novo-aasld-2026-semaglutide-efruxifermin-mash-liver-data PepsReview en 2026-11-04 semaglutide MASH, AASLD 2026, efruxifermin, MASH liver disease, GLP-1 liver data, ESSENCE trial, resmetirom https://pepsreview.com/articles/tga-approves-first-oral-glp1-weight-loss-tablet-australia PepsReview en 2026-11-03 TGA Wegovy tablet, oral semaglutide Australia, GLP-1 tablet approval, Wegovy pill, unapproved peptides, peptide testing, GLP-1 regulation https://pepsreview.com/articles/fda-approves-once-weekly-insulin-children-type-2-diabetes PepsReview en 2026-11-03 insulin icodec, once-weekly insulin, pediatric type 2 diabetes, FDA approval, Awiqli, peptide therapeutics, GLP-1 https://pepsreview.com/articles/nine-in-ten-eligible-teens-received-neither-glp1-nor-surgery PepsReview en 2026-11-03 adolescent obesity, GLP-1 access, bariatric surgery adolescents, JAMA Pediatrics, semaglutide adolescents, pediatric obesity treatment, insurance coverage GLP-1